ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Intrinsic Value
ASKA Pharmaceutical Holdings Co., Ltd. engages in the management of its group companies which are involved in the manufacture and sale of pharmaceuticals, quasi-drugs, food, veterinary drugs, feeds, f... [ Read More ]
The intrinsic value of one
ASKA Pharmaceutical Holdings Co Ltd
stock under the Base Case scenario is
129 512.4
JPY.
Compared to the current market price of 2 263 JPY,
ASKA Pharmaceutical Holdings Co Ltd
is
Undervalued by 98%.
ASKA Pharmaceutical Holdings Co Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
ASKA Pharmaceutical Holdings Co Ltd's market capitalization is 64.1B JPY.
ASKA Pharmaceutical Holdings Co Ltd stock price is 2 263 JPY.
ASKA Pharmaceutical Holdings Co Ltd stock price (2263 JPY) is 98% less than its Intrinsic Value (129 512.4 JPY).
ASKA Pharmaceutical Holdings Co Ltd stock price (2263 JPY) is 1% less than its DCF Value (2 293.76 JPY). Open DCF Valuation
ASKA Pharmaceutical Holdings Co Ltd stock price (2263 JPY) is 99% less than its Relative Value (256 731.04 JPY). Open Relative Valuation
ASKA Pharmaceutical Holdings Co Ltd has upside potential of 7% compared to the average analyst price target.
Open Wall St Estimates
ASKA Pharmaceutical Holdings Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 11%.
ASKA Pharmaceutical Holdings Co Ltd's Revenue has grown by 4% over the past 12 months.
ASKA Pharmaceutical Holdings Co Ltd's Revenue is forecast to grow at a rate of 3% per year over the next 3 years.
ASKA Pharmaceutical Holdings Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 4% to 7%.
ASKA Pharmaceutical Holdings Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
ASKA Pharmaceutical Holdings Co Ltd's Revenue has been growing by 4% per year for the last 3 years.
ASKA Pharmaceutical Holdings Co Ltd has positive Operating Income for the last twelve months.
ASKA Pharmaceutical Holdings Co Ltd has positive Net Income for the last twelve months.
ASKA Pharmaceutical Holdings Co Ltd has positive three-year average ROE (Return on Equity): 8%. The company is efficient at transforming stockholders' equity into net income.
ASKA Pharmaceutical Holdings Co Ltd has positive Free Cash Flow for the last twelve months.
ASKA Pharmaceutical Holdings Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 6% to 11%.
ASKA Pharmaceutical Holdings Co Ltd has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
ASKA Pharmaceutical Holdings Co Ltd's Altman Z-Score is equal to 2.84.
ASKA Pharmaceutical Holdings Co Ltd has positive Gross Profit for the last twelve months.
ASKA Pharmaceutical Holdings Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (20B JPY) than debt (10B JPY).
ASKA Pharmaceutical Holdings Co Ltd's long-term assets (95B JPY) exceed its long-term liabilties (34B JPY).
ASKA Pharmaceutical Holdings Co Ltd's short-term assets (62B JPY) exceed its short-term liabilties (22B JPY).
ASKA Pharmaceutical Holdings Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.17.
ASKA Pharmaceutical Holdings Co Ltd earns more than enough operating income (6B JPY) to safely cover interest payments on its debt (46m JPY).
Fundamental Analysis
ASKA Pharmaceutical Holdings Co Ltd
Balance Sheet Decomposition
ASKA Pharmaceutical Holdings Co Ltd
| Current Assets | 62B |
| Cash & Short-Term Investments | 20.4B |
| Receivables | 18.3B |
| Other Current Assets | 23.3B |
| Non-Current Assets | 32.9B |
| Long-Term Investments | 15.3B |
| PP&E | 10.6B |
| Intangibles | 3.2B |
| Other Non-Current Assets | 3.8B |
| Current Liabilities | 21.5B |
| Accounts Payable | 8.6B |
| Short-Term Debt | 3.2B |
| Other Current Liabilities | 9.7B |
| Non-Current Liabilities | 12.9B |
| Long-Term Debt | 6.9B |
| Other Non-Current Liabilities | 6B |
Earnings Waterfall
ASKA Pharmaceutical Holdings Co Ltd
|
Revenue
|
62B
JPY
|
|
Cost of Revenue
|
-32.2B
JPY
|
|
Gross Profit
|
29.9B
JPY
|
|
Operating Expenses
|
-24.3B
JPY
|
|
Operating Income
|
5.6B
JPY
|
|
Other Expenses
|
920m
JPY
|
|
Net Income
|
6.5B
JPY
|
Free Cash Flow Analysis
ASKA Pharmaceutical Holdings Co Ltd
Profitability Score
Profitability Due Diligence
ASKA Pharmaceutical Holdings Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
ASKA Pharmaceutical Holdings Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
ASKA Pharmaceutical Holdings Co Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
ASKA Pharmaceutical Holdings Co Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
ASKA Pharmaceutical Holdings Co Ltd
According to Wall Street analysts, the average 1-year price target for
ASKA Pharmaceutical Holdings Co Ltd
is 2 422.5 JPY
with a low forecast of 2 373.5 JPY and a high forecast of 2 520 JPY.
Shareholder Return
Price
ASKA Pharmaceutical Holdings Co Ltd
| Average Annual Return | -2.68% |
| Standard Deviation of Annual Returns | 39.42% |
| Max Drawdown | -37% |
| Market Capitalization | 64.1B JPY |
| Shares Outstanding | 28 283 200 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
ASKA Pharmaceutical Holdings Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
ASKA Pharmaceutical Holdings Co., Ltd. engages in the management of its group companies which are involved in the manufacture and sale of pharmaceuticals, quasi-drugs, food, veterinary drugs, feeds, feed additives, and medical devices. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-04-01. The firm mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
You don't have any saved screeners yet
